Nanotechnology Assisted Chemotherapy for Targeted Cancer Treatment: Recent Advances and Clinical Perspectives

2020 ◽  
Vol 20 (27) ◽  
pp. 2442-2458
Author(s):  
Huan-Rong Lan ◽  
Zhi-Qiang Wu ◽  
Li-Hua Zhang ◽  
Ke-Tao Jin ◽  
Shi-Bing Wang
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Chemotherapeutic Agents ◽  
Clinical Settings ◽  
Effective Parameters ◽  
Design And Synthesis ◽  
Recent Advances ◽  
Theranostic Agents ◽  
Reduced Toxicity ◽  
Encapsulation Methods

Nanotechnology has recently provided exciting platforms in the field of anticancer research with promising potentials for improving drug delivery efficacy and treatment outcomes. Nanoparticles (NPs) possess different advantages over the micro and bulk therapeutic agents, including their capability to carry high payloads of drugs, with prolonged half-life, reduced toxicity of the drugs, and increased targeting efficiency. The wide variety of nanovectors, coupled with different conjugation and encapsulation methods available for different theranostic agents provide promising opportunities to fine-tune the pharmacological properties of these agents for more effective cancer treatment methods. This review discusses applications of NPs-assisted chemotherapy in preclinical and clinical settings and recent advances in design and synthesis of different nanocarriers for chemotherapeutic agents. Moreover, physicochemical properties of different nanocarriers, their impacts on different tumor targeting strategies and effective parameters for efficient targeted drug delivery are discussed. Finally, the current approved NPs-assisted chemotherapeutic agents for clinical applications and under different phases of clinical trials are discussed.

Immunoliposomes: Synthesis, Structure, and their Potential as Drug Delivery Carriers

2020 ◽  
Vol 16 (4) ◽  
pp. 306-319 ◽  
Author(s):  
Divya Sandeep ◽  
Nour M. AlSawaftah ◽  
Ghaleb A. Husseini
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Drug Targeting ◽  
Therapeutic Potential ◽  
Chemotherapeutic Agents ◽  
Recent Advances

Immunoliposomes have emerged as attractive drug targeting vehicles for cancer treatment. This review presents the recent advances in the design of immunoliposomes encapsulating a variety of chemotherapeutic agents. We provided an overview of different routes that can be used to conjugate antibodies to the surfaces of liposomes, as well as several examples of stimuliresponsive immunoliposome systems and their therapeutic potential for cancer treatment.

scholarly journals Recent Advances in Nanoparticle Shape and Composition Regulation Based on Galvanic Replacement for Cancer Treatment

2018 ◽  
Author(s):  
Woojun Shin ◽  
Kyungtae Kang ◽  
Hongje Jang
Keyword(s):  
Drug Delivery ◽  
Ion Exchange ◽  
Cancer Treatment ◽  
Synthetic Methods ◽  
Galvanic Replacement ◽  
Future Outlook ◽  
Composition Control ◽  
Nanoparticle Shape ◽  
Recent Advances ◽  
Constituent Elements

Owing to their unique physicochemical properties, nanoparticles are used in a variety of ways in the field of cancer treatment, including imaging, drug delivery, and photothermal and photodynamic therapies. The fascinating properties of nanoparticles are determined by their size, morphology, and constituent elements, and various synthetic methods and post-synthetic techniques have been applied to control these factors. Herein, we present examples of shape and composition control through galvanic replacement, a technique that exploits redox potential differences between elements to induce spontaneous ion-exchange and highlight its specific contributions to cancer treatment applications. The present article identifies the recent advances in nanoparticle formation techniques and discusses the future outlook of the field.

The Role of Iron in Doxorubicin-Induced Cardiotoxicity: Recent Advances and Implication for Drug Delivery

2021 ◽  
Author(s):  
Yan Qin ◽  
Tao Guo ◽  
Zheng Wang ◽  
Yanjun Zhao
Keyword(s):  
Drug Delivery ◽  
Clinical Application ◽  
Chemotherapeutic Agents ◽  
Anthracycline Antibiotic ◽  
Recent Advances

As an anthracycline antibiotic, doxorubicin (DOX) is one of the most potent and widely used chemotherapeutic agents for treating various types of tumors. Unfortunately, clinical application of this drug results...

The Design and Application of Nanomaterials as Drug Carriers in Cancer Treatment

2020 ◽  
Vol 27 (36) ◽  
pp. 6112-6135
Author(s):  
Jia Hou ◽  
Xiaoyan Sun ◽  
Ying Huang ◽  
Shaohua Yang ◽  
Junjie Liu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Cancer Treatment ◽  
Controlled Drug Release ◽  
Drug Carriers ◽  
Control Drug ◽  
Normal Tissues ◽  
Drug Concentrations ◽  
Treatment Technologies ◽  
Reduced Toxicity

The development of new medical cancer treatment technologies is of great significance in reducing cancer mortality. Traditional clinical cancer therapy has a short drug action time, difficulty in accurately targeting tumour tissues and high levels of toxicity in normal tissues. With the development of nanotechnology, nanomaterials have been used as drug carriers to specifically target cancer cells and release drugs into the tumour environment. This technique has become an important research hotspot in cancer treatment. There are several advantages of using nanomaterials for cancer treatment that improve the efficacy of drug delivery, including increased drug concentrations in the targeted tumour area, reduced toxicity in normal tissues and controlled drug release. In this work, we describe the latest research development on the use of nanomaterials for drug delivery in cancer treatment and explore related mechanistic pathways. In addition, the methods used to control drug release into the targeted area using nanocarriers are reviewed in detail. Overall, we present current achievements using nanomaterials and nanotechnologies in cancer treatment, followed by current challenges and future prospects.

scholarly journals GdxFe3-xO4 nanoparticles with silane shell as potential theranostic agent for cancer treatment

2022 ◽  
Vol 2155 (1) ◽  
pp. 012006
Author(s):  
Alexandr V. Zibert ◽  
Lana I. Lissovskaya ◽  
Ilya V. Korolkov ◽  
Maxim V. Zdorovets
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Ftir Spectroscopy ◽  
Biomedical Applications ◽  
Mri Imaging ◽  
Shell Nanoparticles ◽  
Theranostic Agent ◽  
Theranostic Agents

Abstract In this study of GdxFe3-xO4 compound core silane shell nanoparticles method is represented.Samples were analyzed with SEM, EDA and FTIR spectroscopy. Further attaching of carborane compounds is discussed. Products can be used in biomedical applications for MRI imaging and drug delivery for NCT, so can be considered as potential theranostic agents for cancer treatment.

scholarly journals Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations

Polymers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 4400
Author(s):  
Ali Sartaj ◽  
Zufika Qamar ◽  
Farheen Fatima Qizilbash ◽  
Annu ◽  
Shadab Md ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Side Effects ◽  
Cancer Treatment ◽  
Polymeric Nanoparticles ◽  
Breast Cancer Treatment ◽  
Chemotherapeutic Agents ◽  
First Line ◽  
Chemotherapy Drugs ◽  
Polymeric Nanoparticle

This manuscript aims to provide the latest update on polymeric nanoparticle drug delivery system for breast cancer treatment after 2015 and how research-oriented it is based on the available research data. Therefore, the authors have chosen breast cancer which is the most frequent and common reason for mortality in women worldwide. The first-line treatment for breast cancer treatment is chemotherapy, apart from surgery, radiation and hormonal therapy. Chemotherapy is associated with lesser therapeutics and undesirable side effects and hence. In addition, drug resistance affects the therapeutic dose to the target site. Although various nano-based formulations have been developed for effective treatment, the polymeric nanoparticles effectively avoid the lacunae of conventional chemotherapy. There has been an effort made to understand the chemotherapy drugs and their conventional formulation-related problems for better targeting and effective drug delivery for breast cancer treatment. Thus, the polymeric nanoparticles as a strategy overcome the associated problems with resulting dose reduction, enhanced bioavailability, reduced side effects, etc. This present review has compiled the research reports published from 2015 to 2021 from different databases, such as PubMed, Google Scholar, ScienceDirect, which are related to breast cancer treatment in which the drug delivery of numerous chemotherapeutic agents alone or in combination, including phytoconstituents formulated into various polymer-based nanoparticles.

scholarly journals A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Weiwei Mu ◽  
Qihui Chu ◽  
Yongjun Liu ◽  
Na Zhang
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Delivery ◽  
Chemotherapeutic Agents ◽  
Therapeutic Effects ◽  
Cancer Treatments ◽  
Powerful Strategy

AbstractAlthough notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer patients. Chemoimmunotherapy, combining chemotherapeutics and immunotherapeutic drugs, has emerged as a promising approach for cancer treatment, with the advantages of cooperating two kinds of treatment mechanism, reducing the dosage of the drug and enhancing therapeutic effect. Moreover, nano-based drug delivery system (NDDS) was applied to encapsulate chemotherapeutic agents and exhibited outstanding properties such as targeted delivery, tumor microenvironment response and site-specific release. Several nanocarriers have been approved in clinical cancer chemotherapy and showed significant improvement in therapeutic efficiency compared with traditional formulations, such as liposomes (Doxil®, Lipusu®), nanoparticles (Abraxane®) and micelles (Genexol-PM®). The applications of NDDS to chemoimmunotherapy would be a powerful strategy for future cancer treatment, which could greatly enhance the therapeutic efficacy, reduce the side effects and optimize the clinical outcomes of cancer patients. Herein, the current approaches of cancer immunotherapy and chemoimmunotherapy were discussed, and recent advances of NDDS applied for chemoimmunotherapy were further reviewed.

Prostatic Acid Phosphatase (PAP) Differentiated Ultracytochemically from Lysosomal Acid Phosphate in the Rat with a PAP/Specific Substrate, Phosphorylcholine

1975 ◽  
Vol 33 ◽  
pp. 450-451
Author(s):  
W. Allen Shannon ◽  
José A. Serrano ◽  
Hannah L. Wasserkrug ◽  
Anna A. Serrano ◽  
Arnold M. Seligman
Keyword(s):  
Acid Phosphatase ◽  
Phosphate Buffer ◽  
Prostatic Carcinoma ◽  
Prostatic Acid Phosphatase ◽  
Chemotherapeutic Agents ◽  
Specific Substrate ◽  
Acid Phosphate ◽  
Lysosomal Acid ◽  
Design And Synthesis ◽  
New Chemotherapeutic Agents

During the design and synthesis of new chemotherapeutic agents for prostatic carcinoma based on phosphorylated agents which might be enzyme-activated to cytotoxicity, phosphorylcholine, [(CH3)3+NCH2CH2OPO3Ca]Cl-, has been indicated to be a very specific substrate for prostatic acid phosphatase (PAP). This phenomenon has led to the development of specific histochemical and ultracytochemical methods for PAP using modifications of the Gomori lead method for acid phosphatase. Comparative histochemical results in prostate and kidney of the rat have been published earlier with phosphorylcholine (PC) and β-glycerophosphate (βGP). We now report the ultracytochemical results.Minced tissues were fixed in 3% glutaraldehyde-0.1 M phosphate buffered (pH 7.4) for 1.5 hr and rinsed overnight in several changes of 0.05 M phosphate buffer (pH 7.0) containing 7.5% sucrose. Tissues were incubated 30 min to 2 hr in Gomori acid phosphatase medium (2) containing 0.1 M substrate, either PC or βGP.

Sign in / Sign up

Export Citation Format

Share Document